bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the transaction, the insider now directly owns 62,305 shares in the company, valued at approximately $9,431,730.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of bluebird bio, Inc. (NASDAQ BLUE) traded up $13.30 during trading on Friday, hitting $156.25. 1,240,575 shares of the stock were exchanged, compared to its average volume of 816,660.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. During the same quarter in the previous year, the firm posted ($2.07) earnings per share. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. equities research analysts forecast that bluebird bio, Inc. will post -6.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 35,000 Shares” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/03/bluebird-bio-inc-blue-insider-jeffrey-t-walsh-sells-35000-shares.html.

BLUE has been the subject of several recent research reports. Jefferies Group LLC reissued a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a research report on Friday, August 11th. Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a report on Friday. Finally, Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target on the stock in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $131.05.

A number of hedge funds have recently made changes to their positions in BLUE. BNP Paribas Arbitrage SA increased its holdings in bluebird bio by 6.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,444 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 330 shares during the period. Alps Advisors Inc. increased its holdings in bluebird bio by 21.5% in the 3rd quarter. Alps Advisors Inc. now owns 44,898 shares of the biotechnology company’s stock valued at $6,167,000 after buying an additional 7,936 shares during the period. World Asset Management Inc bought a new stake in bluebird bio in the 3rd quarter valued at $230,000. Principal Financial Group Inc. increased its holdings in bluebird bio by 52.0% in the 3rd quarter. Principal Financial Group Inc. now owns 69,185 shares of the biotechnology company’s stock valued at $9,503,000 after buying an additional 23,682 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in bluebird bio by 25.9% in the 3rd quarter. Daiwa Securities Group Inc. now owns 21,263 shares of the biotechnology company’s stock valued at $2,920,000 after buying an additional 4,368 shares during the period.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.